JP2022512912A5 - - Google Patents

Info

Publication number
JP2022512912A5
JP2022512912A5 JP2021524020A JP2021524020A JP2022512912A5 JP 2022512912 A5 JP2022512912 A5 JP 2022512912A5 JP 2021524020 A JP2021524020 A JP 2021524020A JP 2021524020 A JP2021524020 A JP 2021524020A JP 2022512912 A5 JP2022512912 A5 JP 2022512912A5
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
acid sequence
epitope
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021524020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512912A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060355 external-priority patent/WO2020097393A1/en
Publication of JP2022512912A publication Critical patent/JP2022512912A/ja
Publication of JP2022512912A5 publication Critical patent/JP2022512912A5/ja
Withdrawn legal-status Critical Current

Links

JP2021524020A 2018-11-07 2019-11-07 アルファウイルス新生抗原ベクター及びインターフェロン阻害因子 Withdrawn JP2022512912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862756980P 2018-11-07 2018-11-07
US62/756,980 2018-11-07
PCT/US2019/060355 WO2020097393A1 (en) 2018-11-07 2019-11-07 Alphavirus neoantigen vectors and interferon inhibitors

Publications (2)

Publication Number Publication Date
JP2022512912A JP2022512912A (ja) 2022-02-07
JP2022512912A5 true JP2022512912A5 (https=) 2022-11-15

Family

ID=70611178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524020A Withdrawn JP2022512912A (ja) 2018-11-07 2019-11-07 アルファウイルス新生抗原ベクター及びインターフェロン阻害因子

Country Status (9)

Country Link
US (1) US20220125919A1 (https=)
EP (1) EP3877531A4 (https=)
JP (1) JP2022512912A (https=)
KR (1) KR20210090650A (https=)
CN (1) CN112912507A (https=)
AU (1) AU2019374874A1 (https=)
CA (1) CA3119752A1 (https=)
IL (1) IL282793A (https=)
WO (1) WO2020097393A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
US20230031287A1 (en) * 2019-12-13 2023-02-02 Northwestern University Method and composition for enhancing the immune response
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022011429A1 (en) * 2020-07-17 2022-01-20 The University Of Western Australia Methods to increase response to immune checkpoint modulation
CN111991569B (zh) * 2020-07-22 2021-09-28 华中科技大学 一种双靶向乳腺癌细胞及其淋巴结转移灶的纳米颗粒、制备方法及应用
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
GB202020063D0 (en) * 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
GB202020061D0 (en) * 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
EP4583861A1 (en) * 2022-09-09 2025-07-16 Spark Therapeutics, Inc. Enhancing non-viral dna delivery and expression
WO2025090933A1 (en) * 2023-10-26 2025-05-01 The Trustees Of The University Of Pennsylvania Methods and compositions comprising a type i interferon (ifn1) inhibitor
CN117457069A (zh) * 2023-10-30 2024-01-26 南方医科大学南方医院 一种基于m7G相关基因突变对肝癌进行分型的方法和生存预测模型构建
WO2026013528A1 (en) * 2024-07-08 2026-01-15 Ramot At Tel-Aviv University Ltd. A method and composition for treating cancer with an anti-ly6e antibody to reprogram cd8+ t cells for cancer immunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU2003222068A1 (en) * 2002-03-25 2003-10-13 University Of North Carolina At Chapel Hill Improved methods for achieving expression from alphavirus vectors
EP2848692B1 (en) * 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
US20110117124A1 (en) * 2007-08-31 2011-05-19 Sadoff Jerald C Enhancement of transgene expression from viral-based vaccine vectors by expression of suppressors of the type i interferon response
JP2020500552A (ja) * 2016-11-23 2020-01-16 グリットストーン オンコロジー インコーポレイテッド 新生抗原のウイルスによる送達方法
CA3060569A1 (en) * 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
JP2021524247A (ja) * 2018-05-23 2021-09-13 グリットストーン バイオ インコーポレイテッド 免疫チェックポイント阻害剤の共発現ベクター

Similar Documents

Publication Publication Date Title
JP2022512912A5 (https=)
JP2021525076A5 (https=)
JP2023526495A5 (https=)
JP2023541108A5 (https=)
JP2021524247A5 (https=)
JP2022534282A5 (https=)
JP2023523414A5 (https=)
Barry et al. Protection against mycoplasma infection using expression-library immunization
JP2023523413A5 (https=)
Johansson et al. Intradermal electroporation of naked replicon RNA elicits strong immune responses
JP2021501572A5 (https=)
RU2019119272A (ru) Вирусная доставка неоантигенов
JP2022539417A5 (https=)
CN112368386A (zh) 共有抗原
JP2022512912A (ja) アルファウイルス新生抗原ベクター及びインターフェロン阻害因子
TW201907937A (zh) 阿爾法病毒新抗原載體
CN112351793A (zh) 免疫检查点抑制剂共表达载体
JP2023521662A5 (https=)
US12018252B2 (en) Methods and compositions for identifying neoantigens for use in treating cancer
JP2018508212A5 (https=)
FI3652606T3 (fi) Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon
CN118556131A (zh) 用于蛋白质表达的mRNA及其模板
JP2024517884A5 (https=)
CN105802909A (zh) 具有her2特异性tcr的t细胞制备物及其用途
WO2025102994A1 (zh) 基于i型内含子的rna体外环化与滚环翻译的方法及其应用